Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized, dose-ranging, efficacy and tolerability study in chronic kidney disease patients with hyperphosphatemia on hemodialysis. Patient participation in the study is approximately 10 weeks in duration.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ilypsa

Criteria

Inclusion Criteria:

• CKD patients on dialysis

• Prior successful use of phosphate binder

• Signed informed consent

Exclusion Criteria:

• Previous intolerance to polymer-based phosphate binders

• Kidney transplant planned within 3 months

• Pregnant or lactating women, or women of child bearing potential not using an acceptable form of birth control

• Clinically significant liver disease

• History of bowel obstruction or other significant gastrointestinal disorder

Additional study entry criteria will be evaluated during initial screening.